Oncology Drugs - Angola

Angola

The market of Oncology Drugs market in Angola is expected to witness significant growth in the coming years.
According to projections, the revenue in this market is estimated to reach US$47.17m in 2024.
Furthermore, it is anticipated that the market will experience a steady annual growth rate (CAGR 2024-2029) of 6.75%, leading to a market volume of US$65.38m by 2029.
When compared globally, it is worth noting that United States is expected to generate the highest revenue in this market, with an estimated value of US$103,900.00m in 2024.
Despite facing challenges in healthcare infrastructure, Angola is experiencing an increasing demand for innovative oncology drugs.

Key regions: France, Europe, United Kingdom, Brazil, India

Market

Region

Region comparison

Currency

Analyst Opinion

The Oncology Drugs market in Angola has been steadily growing over the past few years, with an increasing demand for cancer treatments in the region.

Customer preferences: Angolan patients are showing a growing preference for more advanced and effective cancer treatments, leading to an increase in demand for oncology drugs. Patients are also becoming more aware of the importance of early detection and treatment, leading to an increase in cancer diagnosis rates.

Trends in the market: The oncology drugs market in Angola is seeing an increase in the availability of new and innovative treatments, as global pharmaceutical companies expand their operations in the region. The market is also seeing an increase in the availability of generic oncology drugs, which are more affordable for patients.

Local special circumstances: Angola has a high incidence of cancer, with breast, cervical, and prostate cancers being the most common. The country also has a shortage of oncologists and limited access to cancer treatment facilities, leading to patients often having to travel long distances to receive treatment.

Underlying macroeconomic factors: The Angolan government has been investing heavily in healthcare infrastructure and increasing access to healthcare services, including cancer treatment facilities. The country's economy has also been growing, leading to an increase in disposable income and the ability to afford more expensive cancer treatments. However, the market is still facing challenges such as a lack of skilled healthcare professionals, limited access to funding, and a lack of awareness of cancer prevention and early detection.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.